Compare Sun Pharma with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs STERLING BIOTECH - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA STERLING BIOTECH SUN PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 21.8 -0.4 - View Chart
P/BV x 2.5 0.0 17,892.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 SUN PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
STERLING BIOTECH
Dec-13
SUN PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs67911 6,464.8%   
Low Rs3753 11,041.2%   
Sales per share (Unadj.) Rs121.126.8 451.9%  
Earnings per share (Unadj.) Rs13.4-15.0 -89.4%  
Cash flow per share (Unadj.) Rs20.7-5.5 -378.6%  
Dividends per share (Unadj.) Rs2.750-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs172.654.9 314.5%  
Shares outstanding (eoy) m2,399.26267.87 895.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.40.3 1,678.2%   
Avg P/E ratio x39.4-0.5 -8,480.3%  
P/CF ratio (eoy) x25.5-1.3 -2,003.0%  
Price / Book Value ratio x3.10.1 2,411.7%  
Dividend payout %20.60-   
Avg Mkt Cap Rs m1,264,6501,862 67,929.9%   
No. of employees `00017.51.4 1,292.5%   
Total wages/salary Rs m59,671547 10,912.7%   
Avg. sales/employee Rs Th16,608.15,303.3 313.2%   
Avg. wages/employee Rs Th3,409.6403.8 844.3%   
Avg. net profit/employee Rs Th1,833.8-2,959.0 -62.0%   
INCOME DATA
Net Sales Rs m290,6597,181 4,047.8%  
Other income Rs m10,25543 24,072.5%   
Total revenues Rs m300,9147,223 4,165.9%   
Gross profit Rs m63,076947 6,661.3%  
Depreciation Rs m17,5332,543 689.4%   
Interest Rs m5,5534,377 126.9%   
Profit before tax Rs m50,246-5,931 -847.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,1440-   
Tax Rs m6,009-1,924 -312.3%   
Profit after tax Rs m32,093-4,007 -801.0%  
Gross profit margin %21.713.2 164.6%  
Effective tax rate %12.032.4 36.9%   
Net profit margin %11.0-55.8 -19.8%  
BALANCE SHEET DATA
Current assets Rs m310,69214,335 2,167.4%   
Current liabilities Rs m173,39649,809 348.1%   
Net working cap to sales %47.2-494.0 -9.6%  
Current ratio x1.80.3 622.6%  
Inventory Days Days99403 24.6%  
Debtors Days Days112171 65.4%  
Net fixed assets Rs m232,47755,432 419.4%   
Share capital Rs m2,399268 895.6%   
"Free" reserves Rs m411,69113,935 2,954.3%   
Net worth Rs m414,09114,701 2,816.7%   
Long term debt Rs m15,2269,478 160.6%   
Total assets Rs m646,93873,988 874.4%  
Interest coverage x10.0-0.4 -2,831.1%   
Debt to equity ratio x00.6 5.7%  
Sales to assets ratio x0.40.1 462.9%   
Return on assets %5.80.5 1,161.7%  
Return on equity %7.8-27.3 -28.4%  
Return on capital %10.2-6.4 -158.2%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m66,0251,860 3,550.1%   
Fx outflow Rs m38,61025 155,123.3%   
Net fx Rs m27,4151,835 1,494.1%   
CASH FLOW
From Operations Rs m21,9651,719 1,278.0%  
From Investments Rs m-6,813-3,148 216.4%  
From Financial Activity Rs m-27,3051,426 -1,914.8%  
Net Cashflow Rs m-8,442-3 248,279.4%  

Share Holding

Indian Promoters % 63.7 33.9 187.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 0.0 -  
FIIs % 23.0 9.9 232.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 8.3 39.3 21.1%  
Shareholders   133,026 21,482 619.2%  
Pledged promoter(s) holding % 0.5 55.9 0.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  BIOCON   

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Inflation and Onion Effect: Your Inside Scoop on the Markets(Podcast)

Stock markets remained rangebound this week too. Macroeconomic news globally and domestically remained the focus of the week.

Related Views on News

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

Use My Secret to Increase Your Trading Profits Today

Dec 10, 2019

What to do after every trade.

How We Made 14.64% Trading Profit in Just 2 Days

Dec 12, 2019

A high probability trade that worked to perfection for my subscribers.

Blue Chips Are Passe. Get into these Stocks for Outstanding Gains in 2020(Profit Hunter)

Dec 5, 2019

This corner of the market could provide more returns than blue chips in 2020.

Make the Most of the Smallcap Rebound with These Stocks(Profit Hunter)

Dec 3, 2019

Even amid a gloomy economic scenario, there are smallcaps that have grown earnings over last one and a half year and I believe these could be the strongest candidates for a smallcap rebound.

What Is the IPO Euphoria Signaling Us About the Markets?(The 5 Minute Wrapup)

Dec 2, 2019

2019 will be remembered as the year of great money-making IPOs...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Dec 13, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - ASTRAZENECA PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS